Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Change in Accured Expenses: 2010-2024

Historic Change in Accured Expenses for Whitehawk Therapeutics (WHWK) over the last 14 years, with Dec 2024 value amounting to -$9.8 million.

  • Whitehawk Therapeutics' Change in Accured Expenses rose 116.15% to $985,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$156,000, marking a year-over-year increase of 97.19%. This contributed to the annual value of -$9.8 million for FY2024, which is 7303.79% down from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Change in Accured Expenses of -$9.8 million as of FY2024, which was down 7,303.79% from -$132,000 recorded in FY2023.
  • In the past 5 years, Whitehawk Therapeutics' Change in Accured Expenses ranged from a high of $3.2 million in FY2022 and a low of -$9.8 million during FY2024.
  • Over the past 3 years, Whitehawk Therapeutics' median Change in Accured Expenses value was -$132,000 (recorded in 2023), while the average stood at -$2.2 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Change in Accured Expenses surged by 148.66% in 2020, and later slumped by 7,303.79% in 2024.
  • Whitehawk Therapeutics' Change in Accured Expenses (Yearly) stood at $1.1 million in 2020, then crashed by 876.65% to -$8.4 million in 2021, then skyrocketed by 138.42% to $3.2 million in 2022, then slumped by 104.10% to -$132,000 in 2023, then slumped by 7,303.79% to -$9.8 million in 2024.